Evidence map›Paper›PMID 28539451›Full record

ArticleJournal of virology2017

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.

Rajesh P Ringe, Gabriel Ozorowski, Kimmo Rantalainen, Weston B Struwe, Katie Matthews, Jonathan L Torres, Anila Yasmeen, Christopher A Cottrell, Thomas J Ketas, Celia C LaBranche and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Rajesh P RingeDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, California, USA.
Kimmo RantalainenDepartment of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, California, USA.
Weston B StruweOxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
Katie MatthewsDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Jonathan L TorresDepartment of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, California, USA.
Anila YasmeenDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Christopher A CottrellDepartment of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, California, USA.
Thomas J KetasDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Celia C LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
David C MontefioriDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
Albert CupoDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Max CrispinOxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, California, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, International AIDS Vaccine Initiative Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery, The Scripps Research Institute, La Jolla, California, USA.
Rogier W SandersDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
P J KlasseDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
John P MooreDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA jpm2003@med.cornell.edu.
Cornell University · USScripps Research Institute · USInternational AIDS Vaccine Initiative · USDuke Medical Center · USUniversity of Amsterdam · NLUniversity of Oxford · GB

Funding

Structural studies of native-like SOSIP trimersP01AI110657 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2015 to 2024
$35.4M
NEUTRALIZATION OF PRIMARY HIV1 VIRUSESR37AI036082 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 1998 to 2017
$7.0M
Biophysical Signatures in HIV-1 Env Correlating with Mother-to-Child TransmissionR21AI112389 · NIAID · UNIVERSITY OF WASHINGTON · PI LEE, KELLY KEISEN · 2014 to 2015
$471k
European Research Council 280829NIAID NIH HHS P01 AI110657NIAID NIH HHS R21 AI112389NIAID NIH HHS R37 AI036082
6 · The paper itself

Abstract

Native-like trimers of the SOSIP design are being developed as immunogens in human immunodeficiency virus type 1 (HIV-1) vaccine development programs. These trimers display the epitopes for multiple broadly neutralizing antibodies (bNAbs) but can also expose binding sites for some types of nonneutralizing antibodies (non-NAbs). Among the latter are epitopes in the gp120 V3 region that are highly immunogenic when SOSIP trimers are evaluated in animal models. It is presently uncertain whether antibodies against V3 can interfere with the induction of NAbs, but there are good arguments in favor of suppressing such "off-target" immune responses. Accordingly, we have assessed how to minimize the exposure of V3 non-NAb epitopes and thereby reduce their immunogenicity by introducing

Indexed as

AIDS VaccinesAnimalsAntibodies, NeutralizingAntigens, Viralenv Gene Products, Human Immunodeficiency VirusEpitopes, B-LymphocyteGlycosylationHIV-1HIV AntibodiesHumansPopulation GroupsProtein Processing, Post-TranslationalRabbitsAIDS VaccinesAntibodies, NeutralizingAntigens, Viralenv Gene Products, Human Immunodeficiency VirusEpitopes, B-LymphocyteHIV AntibodiesEnv trimersHIV-1 vaccineV3 region

Identifiers

PMID28539451
PMCPMC5512241
OpenAlexW2617717260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.